<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335924">
  <stage>Registered</stage>
  <submitdate>3/09/2010</submitdate>
  <approvaldate>6/09/2010</approvaldate>
  <actrnumber>ACTRN12610000740099</actrnumber>
  <trial_identification>
    <studytitle>The effect of supplementing fish oil and aspirin on blood levels of factors involved in the resolution of inflammation in healthy men and women</studytitle>
    <scientifictitle>Measurement of anti-inflammatory resolvins and protectins in healthy individuals taking omega-3 fatty acids in combination with aspirin or placebo.</scientifictitle>
    <utrn />
    <trialacronym>OARS-1</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Low level inflammation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>20 healthy men and women will be recruited from the general population by newspaper advertisements. They will be matched for age and gender. They will be asked to take 4 x 1g fish oil capsules daily (Omega Daily, Blackmores Ltd, Australia) supplying 2.4g/day of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA), for 7 days. On the sixth day they will be randomly allocated to take either 3 x 100mg tablets per day of aspirin (Bayer, Australia) or the same number of placebo (microcellulose) tablets. Volunteers will be asked to take aspirin or placebo tablets on both the sixth and seventh days, in addition to the fish oil. Fish oil capsules and aspirin or placebo tablets will be taken orally. Blood samples will be collected at baseline (day 0), and at days 5 and 7.</interventions>
    <comparator>The study will be placebo controlled for aspirin intake. Placebo tablets will contain microcellulose.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma anti-inflammatory resolvins and protectins</outcome>
      <timepoint>Blood samples will be taken at days 0, 5 and 7</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting plasma fatty acids</outcome>
      <timepoint>Blood samples will be taken at days 0, 5 and 7</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Men aged 20-70 years, and post-menopausal women aged less than 70 years will be recruited from the general population by newspaper advertisements. Volunteers will be included if they do not meet any of the criteria for the metabolic syndrome as defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATPIII).</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Smokers, history of cardiovascular or peripheral vascular disease, diabetes, renal disease, liver disease or taking anti-hypertensive agents, lipid lowering drugs, hormone replacement therapy (women only), &gt; 2 standard alcoholic drinks for women and &gt;3 standard alcoholic drinks for men per day, aspirin or non-steroidal anti-inflammatory drugs, omega-3 fatty acids or &gt;2 fish meals per week.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>For the aspirin / placebo: central allocation by a statistician not involved with the trial</concealment>
    <sequence>Computer generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2010</anticipatedstartdate>
    <actualstartdate>7/06/2010</actualstartdate>
    <anticipatedenddate>15/04/2011</anticipatedenddate>
    <actualenddate>7/06/2011</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>21</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Trevor Mori</primarysponsorname>
    <primarysponsoraddress>School of Medicine and Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Perth Hospital Medical Research Foundation</fundingname>
      <fundingaddress>Royal Perth Hospital Medical Research Foundation
PO Box X2213 
Perth WA 6847</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Anne Barden</sponsorname>
      <sponsoraddress>School of Medicine and Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Emilie Mas</othercollaboratorname>
      <othercollaboratoraddress>School of Medicine and Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Kevin Croft</othercollaboratorname>
      <othercollaboratoraddress>School of Medicine and Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The hypothesis is that in healthy humans dietary omega-3 fatty acids and aspirin enhance the formation of the potent antiinflammatory metabolites resolvins and protectins. Specifically, we aim to determine blood resolvin and protectin levels in a randomised controlled trial of aspirin or
placebo in healthy men and women taking omega-3 fatty acids.</summary>
    <trialwebsite />
    <publication>Details of published manuscript 
Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. 
Anne Barden, Emilie Mas, Kevin D. Croft, Michael Phillips, Trevor A. Mori
Journal of Lipid Research 2014; 55: 24012407.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Western Australia</ethicname>
      <ethicaddress>35 Stirling Highway
Crawley 6009
Western Australia</ethicaddress>
      <ethicapprovaldate>22/02/2010</ethicapprovaldate>
      <hrec>RA/4/1/4014</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Professor Trevor Mori</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</address>
      <phone>61-8-9224 0273</phone>
      <fax>61-8-9224 0246</fax>
      <email>trevor.mori@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Professor Trevor Mori</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</address>
      <phone>61-8-9224 0273</phone>
      <fax>61-8-9224 0246</fax>
      <email>trevor.mori@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Trevor Mori</name>
      <address>School of Medicine and Pharmacology
University of Western Australia
GPO Box X2213
Perth WA 6847</address>
      <phone>trevor.mori@uwa.edu.au</phone>
      <fax>61-8-9224 0273</fax>
      <email>61-8-9224 0246</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Trevor Mori</name>
      <address>School of Medicine and Pharmacology,
Medical Research Foundation Building
GPO Box X2213 Perth WA 6848</address>
      <phone>61-8-92240273</phone>
      <fax />
      <email>trevor.mori@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>